research use only
Cat.No.S5836
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| adipocytes, heart and brain cells | Function assay | Affinity constant for inhibition of A1 receptor control of adenylate cyclase in adipocytes, heart and brain cells, Affinity constant=2μM | 6279840 | |||
| adipocytes, heart and brain cells | Function assay | Affinity constant for A2 receptor control of adenylate cyclase in adipocytes, heart and brain cells, Affinity constant=5μM | 6279840 | |||
| 3T3L1 | Function assay | 0.25 mM | 48 hrs | Stimulation of lipolysis in mouse 3T3L1 cells at 0.25 mM after 48 hrs by glycerol release assay | 24597820 | |
| BL21(DE3) pLysS | Function assay | Inhibition of human His-tagged PDE3B catalytic domain expressed in Escherichia coli BL21(DE3) pLysS cells, IC50=0.242μM | 26908025 | |||
| Sf21 | Function assay | Inhibition of human C-terminal His6-tagged PDE2A1 (215 to 900 residues) expressed in sf21 cells, IC50=4μM | 26908025 | |||
| BL21-CodonPlus | Function assay | Inhibition of recombinant human His6-tagged PDE5A (535 to 786 residues)/PDE6C expressed in Escherichia coli BL21-CodonPlus cells using [3H]cGMP as substrate, Ki=8.5μM | 26908025 | |||
| Sf9 | Function assay | 10 mins | Inhibition of human GST-tagged PDE4B expressed in baculovirus infected Sf9 insect cells using cAMP as substrate after 10 mins by PDE-Glo Phosphodiesterase Assay, IC50=28.2μM | 29407965 | ||
| Click to View More Cell Line Experimental Data | ||||||
| Molecular Weight | 222.24 | Formula | C10H14N4O2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 28822-58-4 | -- | Storage of Stock Solutions |
|
|
| Synonyms | Isobutylmethylxanthine, 1-Methyl-3-Isobutylxanthine | Smiles | CC(C)CN1C2=C(C(=O)N(C1=O)C)NC=N2 | ||
|
In vitro |
DMSO
: 45 mg/mL
(202.48 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
PDE3
6.5 μM
PDE4
26.3 μM
PDE5
31.7 μM
|
|---|---|
| In vitro |
IBMX rescues PGE2-induced phosphorylation of AKT inhibited in cells from the EP4LysM mice, which protects against cAMP degradation. |
| In vivo |
IBMX decreases the liver glycogen storage in both species of mice and hyperglycemic rat. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02807415 | Completed | Cystic Fibrosis |
Hannover Medical School|Heidelberg University|University of Giessen |
June 1 2016 | -- |
| NCT03652090 | Completed | Cystic Fibrosis |
Institut National de la Santé Et de la Recherche Médicale France|ABCF2 |
September 1 2010 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.